D'Souza Gypsyamber, Gross Neil D, Pai Sara I, Haddad Robert, Anderson Karen S, Rajan Shirani, Gerber Jennifer, Gillison Maura L, Posner Marshall R
Gypsyamber D'Souza, Shirani Rajan, and Jennifer Gerber, Johns Hopkins Bloomberg School of Public Health; Sara I. Pai, Johns Hopkins Medical Institutions, Baltimore, MD; Neil D. Gross, Oregon Health and Science University, Portland, OR; Robert Haddad, Dana-Farber Cancer Institute, Boston, MA; Karen S. Anderson, Arizona State University, Tempe, AZ; Maura L. Gillison, Ohio State University Comprehensive Cancer Center, Columbus, OH; and Marshall R. Posner, Icahn School of Medicine at Mount Sinai, New York, NY.
J Clin Oncol. 2014 Aug 10;32(23):2408-15. doi: 10.1200/JCO.2014.55.1341. Epub 2014 Apr 28.
To better understand oral human papillomavirus (HPV) infection and cancer risk among long-term sexual partners of patients with HPV-positive oropharyngeal cancer (HPV-OPC).
An oral rinse sample, risk factor survey, cancer history, and oral examination (partners only) were collected from patients with HPV-OPC and their partners. Oral rinse samples were evaluated for 36 types of HPV DNA using PGMY 09/11 primers and line-blot hybridization and HPV16 copy number using quantitative polymerase chain reaction. Oral HPV prevalence was compared with infection among those age 45 to 65 years using National Health and Nutrition Examination Survey (NHANES) 2009-2010.
A total of 164 patients with HPV-OPC and 93 of their partners were enrolled. Patients were primarily men (90%), were never-smokers (51%), and had performed oral sex (97%), with a median age of 56 years; they had a high prevalence of oncogenic oral HPV DNA (61%) and oral HPV16 DNA (54%) at enrollment. Female partners had comparable oncogenic oral HPV prevalence compared with members of the general population of the same age (1.2% v 1.3%). Among the six male partners, no oncogenic oral HPV infections were detected. No precancers or cancers were identified during partner oral cancer screening examinations. However, a history of cervical disease was reported by nine partners (10.3%) and two female patients (11.8%), and three patients (2.0%) reported a previous partner who developed invasive cervical cancer.
Oral HPV16 DNA is commonly detected among patients with HPV-OPC at diagnosis, but not among their partners. Partners of patients with HPV-OPC do not seem to have elevated oral HPV infection compared with the general population.
为了更好地了解人乳头瘤病毒(HPV)阳性口咽癌(HPV-OPC)患者的长期性伴侣的口腔HPV感染情况及癌症风险。
收集HPV-OPC患者及其伴侣的口腔冲洗样本、风险因素调查、癌症病史及口腔检查(仅针对伴侣)。使用PGMY 09/11引物和线性印迹杂交法评估口腔冲洗样本中的36种HPV DNA类型,并使用定量聚合酶链反应评估HPV16拷贝数。将口腔HPV患病率与2009 - 2010年美国国家健康与营养检查调查(NHANES)中45至65岁人群的感染情况进行比较。
共纳入164例HPV-OPC患者及其93名伴侣。患者主要为男性(90%),从不吸烟者(51%),有口交史(97%),中位年龄为56岁;入组时致癌性口腔HPV DNA(61%)和口腔HPV16 DNA(54%)的患病率较高。女性伴侣的致癌性口腔HPV患病率与同年龄普通人群成员相当(1.2%对1.3%)。在六名男性伴侣中,未检测到致癌性口腔HPV感染。在伴侣口腔癌筛查检查中未发现癌前病变或癌症。然而,九名伴侣(10.3%)和两名女性患者(11.8%)报告有宫颈疾病史,三名患者(2.0%)报告有先前伴侣患浸润性宫颈癌。
在诊断时,HPV-OPC患者中普遍检测到口腔HPV16 DNA,但其伴侣中未检测到。与普通人群相比,HPV-OPC患者的伴侣似乎没有更高的口腔HPV感染率。